UNSPSC 51182030: Norboletone or norbolethone

This classification denotes an anabolic steroid with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3BZU2241A, chemically known as 18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- (9ci) but generally known as norbolethone, which bears US NIH Compound Identifier 13108. European Medicines Agency schedules Norboletone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09354MIG. The term NORBOLETHONE is an International Non-Proprietary Name.

Norboletone or norbolethone bears US NLM identifiers UMLS ID C1142715 and NCI Concept Code C90642. SMILES: CCC12CCC3C(C1CCC2(CC)O)CCC4=CC(=O)CCC34.

UNSPSC 51182030 Norboletone or norbolethone, a Commodity code, reflects state and local procurement of pharmaceutical active pharmaceutical ingredients and finished dosage forms through cooperative purchasing agreements. The code sees activity primarily through multi-state procurement vehicles rather than individual jurisdictions; the most recent opportunity shows a state and local government buying pattern centered on generic pharmaceuticals and over-the-counter products distributed across participating facilities, with vendors required to supply through authorized wholesalers and comply with cGMP, DSCSA, and FDA requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with participation from Oregon and other member states. The RFP closed March 26, 2026, and evaluated vendors on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), agreement to a 3 percent administrative fee (5 percent), and price competitiveness (75 percent). Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co.), carry commercial general liability insurance of $5 million per occurrence and professional liability of $2 million, and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats. Awards were to be effective July 1, 2026, with a two-year initial contract term and optional extensions at MMCAP's discretion; no specific set-asides or dollar values were disclosed.